Raf Kinase Inhibitors

MAP kinase pathway consists of kinases such as Raf, MEK1/2, and ERK1/2, etc., that are critical for the proliferation and survival of tumor cells. Aberrant activation of RAF signaling is a frequent finding in human cancers. In addition to a role in controlling tumors with Ras mutations and activated growth factor receptors, Raf kinase inhibitors may harbor therapeutic potential in tumors carrying a BRAF oncogene. Numerous agents have been discovered to block Raf kinase, including many small molecules. These inhibitors prevent the expression of Raf protein, block Ras/Raf interaction, or obstruct its kinase activity. Several Raf kinase inhibitors are currently undergoing clinical evaluation. In 2013, the Raf family kinase inhibitor Sorafenib (BAY 43-9006) was approved by the FDA for the treatment of advanced renal carcinoma. BioVision is proud to offer Sorafenib as well as several other Raf kinase inhibitors for research.